Nature Communications (Jul 2024)

GLP-1 receptor agonists’ impact on cardio-renal outcomes and mortality in T2D with acute kidney disease

  • Heng-Chih Pan,
  • Jui-Yi Chen,
  • Hsing-Yu Chen,
  • Fang-Yu Yeh,
  • Chiao-Yin Sun,
  • Thomas Tao-Min Huang,
  • Vin-Cent Wu

DOI
https://doi.org/10.1038/s41467-024-50199-y
Journal volume & issue
Vol. 15, no. 1
pp. 1 – 10

Abstract

Read online

Abstract Previous studies have explored the effects of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in reducing cardiovascular events in type 2 diabetes. Here we show that GLP-1 RAs are associated with lower risks of mortality, major cardiovascular events (MACEs), and major adverse kidney events (MAKEs) in type 2 diabetes patients with acute kidney disease (AKD). Utilizing global data from the TriNetX database (2002/09/01-2022/12/01) and propensity score matching, we compare 7511 GLP-1 RAs users to non-users among 165,860 AKD patients. The most common causes of AKI are sepsis (55.2%) and cardiorenal syndrome (34.2%). After a median follow-up of 2.3 years, GLP-1 RAs users exhibit reduced risks of mortality (adjusted hazard ratio [aHR]: 0.57), MACEs (aHR: 0.88), and MAKEs (aHR: 0.73). External validation in a multicenter dataset of 1245 type 2 diabetes patients with AKD supports the favorable outcomes. These results emphasize the potential of GLP-1 RAs in individualized treatment for this population.